Home   News   Circadin® receives marketing authorization in Peru
  • Text size: A A A
  • Circadin

  • Recent news

    • Slenyto is now available in Germany
    • Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)

  • Partners

    Partners